Switch Language

 

eLearning Breast MRI

Presenter: Dr Lale Umutlu, Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany

We strive to provide our customers with the latest training and information on topics that matter to the Canadian diagnostic imaging community. On this page you'll find useful webinars that you can enjoy at your leisure.

 

eLearning Breast MRI

Presenter: Dr Lale Umutlu, Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany

 

eLearning Breast MRI

Presenter: Dr Lale Umutlu, Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany

Key Features and Techniques

Leading radiology professionals from five very different locations share their thoughts about coping with patient numbers, shifting expertise to rural areas, and becoming internationally visible.

MRI of the breast has an increasingly important role in routine clinical practice, offering excellent sensitivity for lesion detection and high specificity for lesion characterization. This four-part eLearning webinar includes structured presentations by Dr Umutlu on selected topics:

Key Features and Techniques

Leading radiology professionals from five very different locations share their thoughts about coping with patient numbers, shifting expertise to rural areas, and becoming internationally visible.

MRI of the breast has an increasingly important role in routine clinical practice, offering excellent sensitivity for lesion detection and high specificity for lesion characterization. This four-part eLearning webinar includes structured presentations by Dr Umutlu on selected topics:

E learning breast MRI Part 1

YYMMDD Author/Uploaded by

PART 1

Indications and Applications -

Introduces the specific advantages of MRI relative to other imaging techniques for morphological and functional imaging of breast lesions.

Duration: 12:32 min

E learning breast MRI Part 3

YYMMDD Author/Uploaded by

PART 3

Reporting and Reading –

Describes the role of breast MRI for staging breast cancer and for therapy monitoring.

Duration: 14:12 min

E learning breast MRI Part 2

YYMMDD Author/Uploaded by

PART 2

Techniques –

Reviews the technical specifications for MRI, the role of contrast agents, and the protocols for optimal performance.

Duration: 12:08 min

E learning breast MRI Part 4

YYMMDD Author/Uploaded by

PART 4

Breast MRI Case Studies –

Presents and interprets five real-world examples of particular interest.

Duration: 4:35 min

E learning breast MRI Part 1

YYMMDD Author/Uploaded by

PART 1

Indications and Applications -

Introduces the specific advantages of MRI relative to other imaging techniques for morphological and functional imaging of breast lesions.

Duration: 12:32 min

E learning breast MRI Part 3

YYMMDD Author/Uploaded by

PART 3

Reporting and Reading –

Describes the role of breast MRI for staging breast cancer and for therapy monitoring.

Duration: 14:12 min

E learning breast MRI Part 2

YYMMDD Author/Uploaded by

PART 2

Techniques –

Reviews the technical specifications for MRI, the role of contrast agents, and the protocols for optimal performance.

Duration: 12:08 min

E learning breast MRI Part 4

YYMMDD Author/Uploaded by

PART 4

Breast MRI Case Studies –

Presents and interprets five real-world examples of particular interest.

Duration: 4:35 min

E learning breast MRI Part 1

YYMMDD Author/Uploaded by

PART 1

Indications and Applications -

Introduces the specific advantages of MRI relative to other imaging techniques for morphological and functional imaging of breast lesions.

Duration: 12:32 min

E learning breast MRI Part 2

YYMMDD Author/Uploaded by

PART 2

Techniques –

Reviews the technical specifications for MRI, the role of contrast agents, and the protocols for optimal performance.

Duration: 12:08 min

E learning breast MRI Part 3

YYMMDD Author/Uploaded by

PART 3

Reporting and Reading –

Describes the role of breast MRI for staging breast cancer and for therapy monitoring.

Duration: 14:12 min

E learning breast MRI Part 4

YYMMDD Author/Uploaded by

PART 4

Breast MRI Case Studies –

Presents and interprets five real-world examples of particular interest.

Duration: 4:35 min

.
    References Part 1

    ACR practice parameter for the performance of contrast-enhanced magnetic resonance imaging (MRI) of the breast. Revised 2018 (Resolution 34).

    Carbonaro LA et al. Breast MRI using a high-relaxivity contrast agent: an overview. AJR Am J Roentgenol. 2011;196(4):942-55.

    Cowper SE et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356(9234):1000-1.

    Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15(6):785-90.

    Frenzel T et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43(12):817-28.

    Lauenstein TC et al.&bsp;Nephrogenic systemic fibrosis: Center case review. J Mag Res Imag. 2007;26(5):1198-203.

    Mann RM et al. Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol. 2008;18(7):1307-18.

    Mann RM et al. Breast MRI: EUSOBI recommendations for women's information. Eur Radiol. 2015;25(12):3669-78.

    Partridge SC et al. Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and size. AJR Am J Roentgenol. 2010;194(6):1664-73.

    Rohrer M et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40(11):715-24.

    Sadowski EA et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243(1):148-57.

    Sardanelli F et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46(8):1296-316.

    .

      References Part 2

      ACR practice parameter for the performance of contrast-enhanced magnetic resonance imaging (MRI) of the breast. Revised 2018 (Resolution 34).

      Carbonaro LA et al. Breast MRI using a high-relaxivity contrast agent: an overview. AJR Am J Roentgenol. 2011;196(4):942-55. https://doi.org/10.2214/AJR.10.4974

      Cowper SE et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356(9234):1000-1.

      Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15(6):785-90.

      Frenzel T et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol. 2008;43(12):817-28.

      Lauenstein TC et al. Nephrogenic systemic fibrosis: Center case review. J Mag Res Imag. 2007;26(5):1198-203.

      Mann RM et al. Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol. 2008;18(7):1307-18.

      Mann RM et al. Breast MRI: EUSOBI recommendations for women's information. Eur Radiol. 2015;25(12):3669-78.

      Partridge SC et al. Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and size. AJR Am J Roentgenol. 2010;194(6):1664-73.

      Rohrer M et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40(11):715-24.

      Sadowski EA et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243(1):148-57.

      Sardanelli F et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46(8):1296-316.

      .

        References Part 3

        ACR BI-RADS Atlas®. 5th Edition, 2013

        Bartella L et al. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology. 2006;239(3):686-92.

        Begley JKP et al. In vivo proton magnetic resonance spectroscopy of breast cancer: a review of the literature. Breast Cancer Res. 2012;14(2):207.

        Kuhl CK et al. Contrast-enhanced MR imaging of the breast at 3.0 and 1.5 T in the same patients: initial experience. Radiology. 2006;239(3):666-76.

        Pereira FP et al. Assessment of breast lesions with diffusion-weighted MRI: comparing the use of different b values. AJR Am J Roentgenol. 2009;193(4):1030-5.

        Siegmann KC et al. Current status and new developments in breast MRI. Breast Care (Basel). 2011;6(2);87-92.